Investment Analysts’ Weekly Ratings Updates for Syndax Pharmaceuticals (SNDX)

Several analysts have recently updated their ratings and price targets for Syndax Pharmaceuticals (NASDAQ: SNDX):

• 4/1/2026 – Syndax Pharmaceuticals had its price target raised by The Goldman Sachs Group, Inc. from $28.00 to $34.00. They now have a “buy” rating on the stock.
• 3/31/2026 – Syndax Pharmaceuticals had its price target lowered by Mizuho from $45.00 to $43.00. They now have an “outperform” rating on the stock.
• 3/30/2026 – Syndax Pharmaceuticals had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $40.00 price target on the stock, down from $48.00.
• 3/27/2026 – Syndax Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 3/9/2026 – Syndax Pharmaceuticals had its price target raised by JPMorgan Chase & Co. from $33.00 to $45.00. They now have an “overweight” rating on the stock.
• 3/8/2026 – Syndax Pharmaceuticals was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/2/2026 – Syndax Pharmaceuticals had its price target raised by Citigroup Inc. from $51.00 to $57.00. They now have a “buy” rating on the stock.
• 2/28/2026 – Syndax Pharmaceuticals was downgraded by Wall Street Zen from “hold” to “sell”.
• 2/27/2026 – Syndax Pharmaceuticals was given a new $45.00 price target by Stifel Nicolaus.

Insider Activity

In other Syndax Pharmaceuticals news, CEO Michael A. Metzger sold 17,159 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $21.03, for a total transaction of $360,853.77. Following the transaction, the chief executive officer owned 491,690 shares of the company’s stock, valued at approximately $10,340,240.70. This trade represents a 3.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Keith A. Goldan sold 3,410 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $21.03, for a total value of $71,712.30. Following the transaction, the chief financial officer directly owned 140,429 shares in the company, valued at approximately $2,953,221.87. The trade was a 2.37% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 30,063 shares of company stock worth $628,332. Corporate insiders own 4.10% of the company’s stock.

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.